<DOC>
	<DOCNO>NCT00566501</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy long-term administration 23 mg donepezil sustain release ( SR ) patient moderate severe Alzheimer 's disease . Patients complete study E2020-G000-326 ongoing serious adverse event ( SAEs ) serious adverse drug reaction eligible enter open-label extension study .</brief_summary>
	<brief_title>Open-Label Extension Study 23 mg Donepezil SR Patients With Moderate Severe Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria Patients : 1 . Written informed consent patient ( possible ) patient 's legal guardian representative time Baseline visit , prior begin assessment activity . 2 . Completion study E2020G000326 without ongoing SAEs history serious adverse drug reaction study E2020G000326 . 3 . Patients must enroll present study within 3 day completion study E2020G000326 4 . Health : physically healthy ambulatory ambulatoryaided ( ie , walker cane ) ; correct vision hear sufficient compliance testing procedure . 5 . Comorbid medical condition must wellcontrolled determined investigator . 6 . Patients undergoing treatment selective serotonin reuptake inhibitor ( SSRIs ) may include provided dos within approve dose range specify Physician 's Desk Reference local equivalent 7 . Concomitant Medications : Patients undergo treatment follow medication may enrol study provide follow condition meet : chronic daily benzodiazepine use dose stable within approve dose range ; bronchodilator medication treatment chronic obstructive pulmonary disease ( COPD ) long drug administer via meter dose inhaler within approve dose range ; memantine take dose 20 mg/day less , provide dose stable . 8 . The patient must relative/caregiver supervises regular take drug correct dose alert possible side effect , unless patient 's legal guardian take task . Inclusion Criteria Caregivers . Written inform consent obtain designate caregiver participation study assessment . The caregiver must sufficiently familiar patient ( determined investigator ) provide accurate data . Specifically , caregiver must sufficient contact patient provide accurate report patient 's functioning , must able observe possible adverse event , must able accompany patient visit . It preferable caregiver study E2020G000326 . If replacement caregiver available meet caregiver inclusion/exclusion criterion , patient must discontinue study . Exclusion Criteria Patients : 1 . No caregiver available meet inclusion criterion caregiver . 2 . Patients active clinicallysignificant condition affect absorption , distribution , metabolism study medication ( e.g. , inflammatory bowel disease , gastric duodenal ulcer , hepatic disease , severe lactose intolerance ) . 3 . Known plan elective surgery study period would require general anesthesia administration neuromuscular block agent , succinylcholine , induce paralysis/muscle relaxation . Minor surgery , colonoscopy cataract surgery , permit long require use paralytic agent . 4 . Patients unwilling unable fulfill requirement study . 5 . Use prohibit prior concomitant medication . 6 . Any condition would make patient , opinion investigator , unsuitable study . 7 . Patients take concomitant antidepressant medication know significant anticholinergic effect , tricyclic antidepressant prescribe dos recommend treatment major depression . 8 . Patients swallow difficulty swallow whole tablet . 9 . Patients take alternative medication vitamin and/or herbal product alternative medical technique acupuncture acupressure specifically treatment Alzheimer 's disease . Exclusion Criteria Caregivers . 1 . Caregivers unwilling unable give inform consent otherwise fulfill requirement study . 2 . Any condition would make caregiver , opinion investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>91 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Moderate-to-severe</keyword>
	<keyword>Alzheimer 's</keyword>
	<keyword>Disease</keyword>
</DOC>